Your browser doesn't support javascript.
loading
Phase I/II Dose-Escalation Trial of 3-Fraction Stereotactic Radiosurgery for Resection Cavities From Large Brain Metastases: Health-related Quality of Life Outcomes.
Rahimy, Elham; Dudley, Sara A; von Eyben, Rie; Pollom, Erqi L; Seiger, Kira; Modlin, Leslie; Wynne, Jacob; Fujimoto, Dylann; Jacobs, Lisa R; Chang, Steven D; Gibbs, Iris C; Hancock, Steven L; Adler, John R; Li, Gordon; Choi, Clara Y H; Soltys, Scott G.
Afiliação
  • Rahimy E; Departments of Radiation Oncology.
  • Dudley SA; Department of Radiation Oncology, Johns Hopkins University, Baltimore, MD.
  • von Eyben R; Departments of Radiation Oncology.
  • Pollom EL; Departments of Radiation Oncology.
  • Seiger K; Department of Dermatology, University of California, San Francisco.
  • Modlin L; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, NY.
  • Wynne J; Department of Radiation Oncology, Emory University, Atlanta, GA.
  • Fujimoto D; University of California, Irvine, School of Medicine, Irvine.
  • Jacobs LR; Department of Pediatrics, University of California, Los Angeles.
  • Chang SD; Neurosurgery, Stanford University, Stanford.
  • Gibbs IC; Departments of Radiation Oncology.
  • Hancock SL; Departments of Radiation Oncology.
  • Adler JR; Neurosurgery, Stanford University, Stanford.
  • Li G; Neurosurgery, Stanford University, Stanford.
  • Choi CYH; Department of Radiation Oncology, Santa Clara Valley Medical Center, San Jose, CA.
  • Soltys SG; Departments of Radiation Oncology.
Am J Clin Oncol ; 44(11): 588-595, 2021 11 01.
Article em En | MEDLINE | ID: mdl-34670228
ABSTRACT

OBJECTIVES:

We investigated differences in quality of life (QoL) in patients enrolled on a phase I/II dose-escalation study of 3-fraction resection cavity stereotactic radiosurgery (SRS) for large brain metastases.

METHODS:

Eligible patients had 1 to 4 brain metastases, one of which was a resection cavity 4.2 to 33.5 cm3. European Organization for Research and Treatment of Cancer (EORTC) quality of life questionnaires core-30 (QLQ-30) and brain cancer specific module (QLQ-BN20) were obtained before SRS and at each follow-up. Nine scales were analyzed (global health status; physical, social, and emotional functioning; motor dysfunction, communication deficit, fatigue, insomnia, and future uncertainty). QoL was assessed with mixed effects models. Differences ≥10 points with q-value (adjusted P-value to account for multiplicity of testing) <0.10 were considered significant.

RESULTS:

Between 2009 and 2014, 50 enrolled patients completed 277 QoL questionnaires. Median questionnaire follow-up was 11.8 months. After SRS, insomnia demonstrated significant improvement (q=0.032, -17.7 points at 15 mo post-SRS), and future uncertainty demonstrated significant worsening (q=0.018, +9.9 points at 15 mo post-SRS). Following intracranial progression and salvage SRS, there were no significant QoL changes. The impact of salvage whole brain radiotherapy could not be assessed because of limited data (n=4 patients). In the 28% of patients that had adverse radiation effect, QoL had significant worsening in 3 metrics (physical functioning, q=0.024, emotional functioning q=0.001, and future uncertainty, q=0.004).

CONCLUSIONS:

For patients treated with 3-fraction SRS for large brain metastasis cavities, 8 of 9 QoL metrics were unchanged or improved after initial SRS. Intracranial tumor progression and salvage SRS did not impact QoL. Adverse radiation effect may be associated with at least short-term QoL impairments, but requires further investigation.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Qualidade de Vida / Neoplasias Encefálicas / Radiocirurgia Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Qualidade de Vida / Neoplasias Encefálicas / Radiocirurgia Idioma: En Ano de publicação: 2021 Tipo de documento: Article